Immunocore announces EVP, Research, Development Berman to depart

Immunocore (IMCR) Holdings announced that Dr. David Berman, Executive Vice President, EVP, Research and Development, will leave the Company effective 27 February 2026. Dr. Berman has accepted a Development Head role at a large commercial-stage biotech company. Immunocore does not intend to seek a direct replacement for Dr. Berman and will instead streamline its R&D structure and leverage the existing experienced leadership team. The Company is promoting Dr. Mohammed Dar, its current Chief Medical Officer, and Mark Moyer, its current Head of Regulatory Sciences, to Executive Vice President roles, assuming expanded oversight of clinical development and regulatory strategies.